Armata Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $190.47M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | $2.50M | $-0.27 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $800.00K | $-3.16 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | During market hours | $1.10M | $-3.42 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | During market hours | $1.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $500.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | After market close | $1.20M | $-0.23 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $3.00M | $-0.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | $1.00M | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | During market hours | $1.50M | – | – |
Press releases
Announcements Armata Pharmaceuticals filed with the SEC
Armata Pharmaceuticals Receives U.S. FDA Breakthrough
Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Achieves Key Progress
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the
Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Receives $2.5 Million
Other events · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Secures FDA Fast Track
Regulation FD disclosure · EX-99.1 to Form 8-K
Daniel B. Gilmer, Ph.D. to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Delays Announcement of
Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Receives FDA Qualified
Regulation FD disclosure · EX-99.1 to Form 8-K
FDA agreed that data from the Phase
Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Highlights Positive Results
Regulation FD disclosure · EX-99.1 to Form 8-K
Safety & Tolerability Safety Population (N=50) Phase 2a Complicated SAB Phase 1b Uncomplicated SAB Placebo (N=13) AP - SA02 (N=29)
Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation Deborah Birx, M.D. Chief Executive Officer H.C. Wainwright 27 th Annual Global Investment Conference September 10, 2025 NYSE American: ARMP
Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Positive Topline
Regulation FD disclosure · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Receives $4.65 Million
Other events · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces $10 Million
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Results from the Phase 2 Tail wind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation December 19, 2024 NYSE American: ARMP
Regulation FD disclosure · EX-99.2 to Form 8-K
Armata Pharmaceuticals Announces Third Quarter 2024 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces the Completion
Regulation FD disclosure · EX-99.1 to Form 8-K
Phase 2 Clinical Trials Evaluating Multi-phage Candidates for the Treatment of Adults with Bacteremia due to Staphylococcus
Regulation FD disclosure · EX-99.1 to Form 8-K
at the 2024 Military Health System Research Symposium
Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation August 26, 2024 NYSE American: ARMP
Regulation FD disclosure · EX-99.3 to Form 8-K
Armata Pharmaceuticals Announces Second Quarter 2024 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces First Quarter 2024 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Third Quarter 2023 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Second Quarter
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces New Financing
Material agreement · New financial obligation · Executive or director change · Other events · EX-99.1 to Form 8-K
First Quarter 2023 Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and
Results of operations · EX-99.1 to Form 8-K
Armata Pharmaceuticals Announces Positive Topline
Regulation FD disclosure · EX-99.1 to Form 8-K